Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0328 | 1 | 0.5 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0328 | 1 | 1 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0328 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0328 | 1 | 1 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0328 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0163 | 0 | 0.5 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0328 | 1 | 1 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0328 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.0291 | 0.7743 | 0.5 |
Trypanosoma cruzi | p450 reductase, putative | 0.0328 | 1 | 0.5 |
Chlamydia trachomatis | sulfite reductase | 0.0203 | 0.2407 | 0.5 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0328 | 1 | 0.5 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0203 | 0.2407 | 0.2407 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0328 | 1 | 1 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0291 | 0.7743 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0163 | 0 | 0.5 |
Brugia malayi | FAD binding domain containing protein | 0.0328 | 1 | 1 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0165 | 0.0151 | 0.0151 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0328 | 1 | 0.5 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0328 | 1 | 0.5 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0328 | 1 | 1 |
Leishmania major | p450 reductase, putative | 0.0328 | 1 | 1 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0328 | 1 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0328 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0328 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0328 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0328 | 1 | 0.5 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0328 | 1 | 0.5 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0328 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | = -8 beats min-1 | Intrinsic sympathomimetic action in reserpinized rats | ChEMBL. | 6102605 |
Actvity (functional) | < 25 mmHg | Antihypertensive activity in spontaneously hypertensive rats after peroral administration, | ChEMBL. | 6102605 |
Delta MAP (functional) | = 22 % | Vasodilator activity in ganglion blocked rats. Values denote percent change in mean arterial blood pressure 30 minutes after dosing rats at 3 mg/kg intrvenously | ChEMBL. | 6102605 |
Inhibition (functional) | = 45 % | Beta-adrenergic receptor blockade activity in conscious normotensive rats at a dose of 1.25 mg/kg | ChEMBL. | 6102605 |
Inhibition (functional) | = 53 % | Beta-adrenergic receptor blockade activity in conscious normotensive rats at a dose of 1.25 mg/kg | ChEMBL. | 6102605 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.